 |
|
|
| |
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Week 12 Sustained Virologic Response Rate
|
| |
| |
Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
B.R. Bacon,1M.L. Shiffman,2J.K. Lim,3A. Berman,4V.K. Rustgi,5E.B. Keeffe,6,7and STEALTH C-3 Investigators
1St. Louis University Medical Center, St. Louis, MO, USA 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA 3Yale University Medical Center, New Haven, CT, USA 4Florida Center for Gastroenterology, Largo, FL, USA, 5Georgetown University Medical Center, Washington, DC, USA and 6Romark Institute for Medical Research, Tampa, FL, USA and 7Stanford University Medical Center, Stanford, CA, USA
|
| |
|
|
|
|
|
